Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pieris, an independent biotechnology company advancing its anticalin technology to create protein therapeutics, has appointed Laurent Audoly as chief scientific officer, effective immediately. Dr Audoly brings both pharma and biotech experience with expertise in therapeutic protein drug development.
Subscribe to our email newsletter
Dr Audoly has held research and managerial positions of increasing responsibility, first as senior research scientist, department of inflammation, at Pfizer and then as senior research fellow, department of pharmacology, at Merck & Co. He then joined MedImmune as director of R&D Inflammation and most recently held the position at Merck and Co as Biologics Research Site lead.
Stephen Yoder, CEO of Pieris, said: “Laurent has an impressive track record of leading teams and moving discovery programs successfully from target identification into and through the clinic. In particular, his pharmacology expertise and drug development skills are the precise ingredients we need to maximize the value of our growing therapeutic pipeline. As the company builds and expands its internal and partnered Anticalin pipeline, Laurent’s contribution will be significant.”
Dr Audoly said: “As a keen proponent of targeted therapeutic technologies, I am excited to join Pieris at a stage where the Anticalin approach is beginning to demonstrate its great therapeutic potential. My goal is to combine my experience from big pharma and biotech with the capabilities present at Pieris to bring the full spectrum of R&D operations to the next level.”